EFEK PEMBERIAN LACTOCOCCUS LACTIS D4 TERHADAP DISBIOSIS MIKROBIOTA PADA KANKER KOLOREKTAL TERKAIT KOLITIS
| dc.contributor.author | Muhammad, Iqbal | |
| dc.contributor.other | Muhammad, Iqbal Rivai | |
| dc.contributor.other | Rini, Suswita | |
| dc.date.accessioned | 2026-09-24T23:49:20Z | |
| dc.date.issued | 2024-03-15 | |
| dc.description | Muhammad Iqbal Rivai | |
| dc.description.abstract | Introduction: Muhammad Iqbal, M. Iqbal Rivai, Rini Suswita Abstract Environmental and genetic factors, particularly the gut microbiota, contribute to colorectal cancer (CRC) development. This study explores the relationship between gut microbiota changes and CRC occurrence, development, prognosis, and early detection. Fecal samples are commonly used for non-invasive analysis, allowing effective screening for CRC risk. Methods: A laboratory experimental research design utilizing Sprague Dawley rats induced with azoxymethane (AOM) and Dextran Sodium Sulfate (DSS) was conducted. Thirty rats were categorized into normal, cancer-induced, and treatment groups. Fecal microbiota profiles were analyzed using Next Generation Sequencing (NGS). Data were processed for alpha and beta diversity, revealing microbial community dynamics. Results: Sequencing results confirmed validity, exhibiting varying sequence reads in normal, cancer-induced, and treated rats. Firmicutes dominated at the phylum level, with Bacilli and Clostridia prevalent at the class level. Order-level analysis demonstrated uneven bacterial abundances among samples. Alpha diversity indicated lower diversity in treated rats, while beta diversity revealed compositional similarities between treated and normal rats, distinguishing them from cancer- induced rats. Conclusion: The study provides valuable insights into gut microbiota dynamics in CRC models. Firmicutes dominance, specifically Bacilli and Clostridia classes, underscores microbial composition. Uneven bacterial abundances at different taxonomic levels and reduced alpha diversity in treated rats suggest a potential probiotic effect of Lactococcus lactis D4 in preventing dysbiosis. Beta diversity highlights compositional similarities between treated and normal rats, emphasizing the potential of Lactococcus lactis D4 in modulating gut microbiota composition and mitigating CRC risk. | |
| dc.identifier.uri | https://ailib.my.id/handle/123456789/73514 | |
| dc.language.iso | id | |
| dc.publisher | Universitas Andalas | |
| dc.subject | Colorectal cancer | |
| dc.subject | gut microbiota | |
| dc.subject | Next Generation Sequencing | |
| dc.subject | dysbiosis | |
| dc.subject | probiotic effect | |
| dc.subject.classification | RD Surgery | |
| dc.title | EFEK PEMBERIAN LACTOCOCCUS LACTIS D4 TERHADAP DISBIOSIS MIKROBIOTA PADA KANKER KOLOREKTAL TERKAIT KOLITIS | |
| dc.type | Thesis | |
| dcterms.dateSubmitted | 2024-07-18 | |
| dcterms.references | 1 Marabotto, E. et al. Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review. Cancers (Basel) 14, doi:10.3390/cancers14174254 (2022). 2 Birch, R. J. et al. Inflammatory Bowel Disease-Associated Colorectal Cancer Epidemiology and Outcomes: An English Population-Based Study. Am J Gastroenterol 117, 1858-1870, doi:10.14309/ajg.0000000000001941 (2022). 3 Sanjaya, I. W. B., Lestarini, A. & Bharata, M. D. Y. Karakteristik Klinis pada Pasien Kanker Kolorektal yang Menjalani Kolonoskopi di RSUD Sanjiwani Gianyar Tahun 2019-2020. AMJ (Aesculapius Medical Journal) 3, 43-48 (2023). 4 Astuti, N. S. A., Rafli, R. & Zeffira, L. Profil dan Kesintasan Penderita Kanker Kolorektal di RSUP Dr. M. Djamil Padang. Health and Medical Journal 1, 45-49 (2019). 5 Porter, R. J., Arends, M. J., Churchhouse, A. M. D. & Din, S. Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines. J Crohns Colitis 15, 2131-2141, doi:10.1093/ecco-jcc/jjab102 (2021). 6 Lucafò, M., Curci, D., Franzin, M., Decorti, G. & Stocco, G. Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention. Front Pharmacol 12, 772101, doi:10.3389/fphar.2021.772101 (2021). 7 Ohnishi, S., Hiramoto, K., Ma, N. & Kawanishi, S. Chemoprevention by Aspirin Against Inflammation-Related Colorectal Cancer in Mice. Journal of Clinical Biochemistry and Nutrition, doi:10.3164/jcbn.20-189 (2021). 8 Nardone, O. M., Zammarchi, I., Santacroce, G., Ghosh, S. & Iacucci, M. Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy. Cancers (Basel) 15, doi:10.3390/cancers15082389 (2023). 9 Gupta, A., Madani, R. & Mukhtar, H. Streptococcus bovis endocarditis, a silent sign for colonic tumour. Colorectal Dis 12, 164-171, doi:10.1111/j.1463- 1318.2009.01814.x (2010). 10 Kostic, A. D. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 22, 292-298, doi:10.1101/gr.126573.111 (2012). 11 Viljoen, K. S., Dakshinamurthy, A., Goldberg, P. & Blackburn, J. M. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS One 10, e0119462, doi:10.1371/journal.pone.0119462 (2015). 12 Buc, E. et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One 8, e56964, doi:10.1371/journal.pone.0056964 (2013). 13 Wang, T. et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. Isme j 6, 320-329, doi:10.1038/ismej.2011.109 (2012). 14 Lin, P. C., Li, S. C., Lin, H. P. & Shih, C. K. Germinated Brown Rice Combined With Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. lactis Inhibits Colorectal Carcinogenesis in Rats. Food Science & Nutrition, doi:10.1002/fsn3.864 (2018). 15 Melia, S. & Sugitha, I. KUALITAS DADIH SUSU SAPI MUTAN Lactococcus lactis PADA BEBERAPA LEVEL WAKTU FERMENTASI [The Quality of Dadih Mutan Lactococcus Lactis at Various Fermentation Times]. Journal of the Indonesian Tropical Animal Agriculture 32, 86-90 (2007). 16 Hossain, M. S. et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. Cancers (Basel) 14, doi:10.3390/cancers14071732 (2022). 17 Kasi, A. et al. Molecular Pathogenesis and Classification of Colorectal Carcinoma. Curr Colorectal Cancer Rep 16, 97-106, doi:10.1007/s11888-020-00458-z (2020). 18 Watson, A. & Collins, P. Colon Cancer: A Civilization Disorder. Digestive Diseases, doi:10.1159/000323926 (2011). 19 Paterson, C. & Božić, I. Mathematical Model of Colorectal Cancer Initiation. Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2003771117 (2020). 20 Kámory, E., Olasz, J. & Csuka, O. Somatic APC Inactivation Mechanisms in Sporadic Colorectal Cancer Cases in Hungary. Pathology & Oncology Research, doi:10.1007/s12253-008-9019-y (2008). 21 Kinzler, K. W. & Vogelstein, B. Lessons From Hereditary Colorectal Cancer. Cell, doi:10.1016/s0092-8674(00)81333-1 (1996). 22 Hankey, W., Frankel, W. L. & Groden, J. Functions of the APC Tumor Suppressor Protein Dependent and Independent of Canonical WNT Signaling: Implications for Therapeutic Targeting. Cancer and Metastasis Reviews, doi:10.1007/s10555-017- 9725-6 (2018). 23 Fearon, E. R. Molecular Genetics of Colorectal Cancer. Annual Review of Pathology Mechanisms of Disease, doi:10.1146/annurev-pathol-011110-130235 (2011). 24 Yang, J. et al. Adenomatous Polyposis Coli (APC) Differentially Regulates Β- Catenin Phosphorylation and Ubiquitination in Colon Cancer Cells. Journal of Biological Chemistry, doi:10.1074/jbc.m600831200 (2006). 25 Hiltunen, M. et al. Hypermethylation of the APC (Adenomatous Polyposis Coli) Gene Promoter Region in Human Colorectal Carcinoma. International Journal of Cancer, doi:10.1002/(sici)1097-0215(19970317)70:6<644::aid-ijc3>3.0.co;2-v (1997). 26 Half, E. E., Bercovich, D. & Rozen, P. Familial Adenomatous Polyposis. Orphanet Journal of Rare Diseases, doi:10.1186/1750-1172-4-22 (2009). 27 Misale, S. et al. Emergence of KRAS Mutations and Acquired Resistance to Anti- Egfr Therapy in Colorectal Cancer. Nature, doi:10.1038/nature11156 (2012). 28 Zhang, J., Park, D., Shin, D. M. & Deng, X. Targeting KRAS-mutant Non-Small Cell Lung Cancer: Challenges and Opportunities. Acta Biochimica Et Biophysica Sinica, doi:10.1093/abbs/gmv118 (2016). 29 Bonnot, P. E. & Passot, G. RAS Mutation: Site of Disease and Recurrence Pattern in Colorectal Cancer. Chinese Clinical Oncology, doi:10.21037/cco.2019.08.11 (2019). 30 Varshavi, D. et al. Metabonomics Study of the Effects of Single Copy Mutant KRAS in the Presence or Absence of WT Allele Using Human HCT116 Isogenic Cell Lines. Metabolomics, doi:10.1007/s11306-021-01852-w (2021). 31 Tie, J. et al. KRAS Mutation Is Associated With Lung Metastasis in Patients With Curatively Resected Colorectal Cancer. Clinical Cancer Research, doi:10.1158/1078-0432.ccr-10-1720 (2011). 32 Klein, C. et al. PDEδ Inhibition Impedes the Proliferation and Survival of Human Colorectal Cancer Cell Lines Harboring Oncogenic KRas. International Journal of Cancer, doi:10.1002/ijc.31859 (2018). 33 Lilja, J. et al. Targeting a Broad Spectrum of <i>KRAS</I>-Mutant Cancers by Hyperactivation-Induced Cell Death. doi:10.1101/2022.09.21.508660 (2022). 34 López, I. et al. Different mutation profiles associated to P53 accumulation in colorectal cancer. Gene 499, 81-87, doi:10.1016/j.gene.2012.02.011 (2012). 35 Ryan, K. M., Phillips, A. C. & Vousden, K. H. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13, 332-337, doi:10.1016/s0955- 0674(00)00216-7 (2001). 36 Russo, A. et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23, 7518-7528, doi:10.1200/jco.2005.00.471 (2005). 37 Li, X. L., Zhou, J., Chen, Z. R. & Chng, W. J. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation. World J Gastroenterol 21, 84-93, doi:10.3748/wjg.v21.i1.84 (2015). 38 Iacopetta, B. TP53 mutation in colorectal cancer. Hum Mutat 21, 271-276, doi:10.1002/humu.10175 (2003). 39 Iacopetta, B. et al. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 17, 842-847, doi:10.1093/annonc/mdl035 (2006). 40 Pino, M. S. & Chung, D. C. The Chromosomal Instability Pathway in Colon Cancer. Gastroenterology, doi:10.1053/j.gastro.2009.12.065 (2010). 41 Mazeh, H. et al. The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - A Comprehensive Review. Journal of Cancer, doi:10.7150/jca.5836 (2013). 42 Al–Sohaily, S., Biankin, A. V., Leong, R. W., Kohonen‐Corish, M. & Warusavitarne, J. Molecular Pathways in Colorectal Cancer. Journal of Gastroenterology and Hepatology, doi:10.1111/j.1440-1746.2012.07200.x (2012). 43 Tian, R. et al. ALOX15 as a Suppressor of Inflammation and Cancer: Lost in the Link. Prostaglandins & Other Lipid Mediators, doi:10.1016/j.prostaglandins.2017.01.002 (2017). 44 Kesselring, R. & Fichtner‐Feigl, S. Immune Responses Triggering Colitis and Colitis-Associated Carcinoma. Langenbeck S Archives of Surgery, doi:10.1007/s00423-012-0927-7 (2012). 45 Cawkwell, L. et al. Defective hMSH2/hMLH1 Protein Expression Is Seen Infrequently in Ulcerative Colitis Associated Colorectal Cancers. Gut, doi:10.1136/gut.46.3.367 (2000). 46 Zhu, G. et al. MyD88 Regulates LPS-induced NF-ĸB/MAPK Cytokines and Promotes Inflammation and Malignancy in Colorectal Cancer Cells. Cancer Genomics & Proteomics, doi:10.21873/cgp.20145 (2019). 47 Zhao, Y. et al. Small Molecule GL-V9 Protects Against Colitis-Associated Colorectal Cancer by Limiting NLRP3 Inflammasome Through Autophagy. Oncoimmunology, doi:10.1080/2162402x.2017.1375640 (2017). 48 Clapper, M. L., Cooper, H. S. & Chang, W. C. L. Dextran Sulfate Sodium-Induced Colitis-Associated Neoplasia: A Promising Model for the Development of Chemopreventive Interventions. Acta Pharmacologica Sinica, doi:10.1111/j.1745- 7254.2007.00695.x (2007). 49 Steele, S. R. et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. Dis Colon Rectum 57, 303-310, doi:10.1097/DCR.0b013e3182a586e7 (2014). 50 Demb, J. et al. Risk factors for colorectal cancer significantly vary by anatomic site. BMJ Open Gastroenterol 6, e000313, doi:10.1136/bmjgast-2019-000313 (2019). 51 Gausman, V. et al. Risk Factors Associated With Early-Onset Colorectal Cancer. Clin Gastroenterol Hepatol 18, 2752-2759.e2752, doi:10.1016/j.cgh.2019.10.009 (2020). 52 Larson, E. Community factors in the development of antibiotic resistance. Annu Rev Public Health 28, 435-447, doi:10.1146/annurev.publhealth.28.021406.144020 (2007). 53 Moschos, S. J. & Mantzoros, C. S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63, 317-332, doi:10.1159/000066230 (2002). 54 Aykan, N. F. Red Meat and Colorectal Cancer. Oncol Rev 9, 288, doi:10.4081/oncol.2015.288 (2015). 55 Bradbury, K. E., Murphy, N. & Key, T. J. Diet and colorectal cancer in UK Biobank: a prospective study. Int J Epidemiol 49, 246-258, doi:10.1093/ije/dyz064 (2020). 56 Crosara Teixeira, M., Braghiroli, M. I., Sabbaga, J. & Hoff, P. M. Primary prevention of colorectal cancer: myth or reality? World J Gastroenterol 20, 15060- 15069, doi:10.3748/wjg.v20.i41.15060 (2014). 57 Ji, J., Sundquist, J. & Sundquist, K. Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer: A population-based study in Sweden. Int J Cancer 142, 2003-2010, doi:10.1002/ijc.31228 (2018). 58 Botteri, E. et al. Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway. BMJ Open 7, e017639, doi:10.1136/bmjopen-2017-017639 (2017). 59 Xie, Y. H., Chen, Y. X. & Fang, J. Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 5, 22, doi:10.1038/s41392- 020-0116-z (2020). 60 Hasbullah, H. H. & Musa, M. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward? Int J Mol Sci 22, doi:10.3390/ijms222111941 (2021). 61 Zahavi, D. & Weiner, L. Monoclonal antibodies in cancer therapy. Antibodies 9, 34 (2020). 62 Almeida, A. et al. A new genomic blueprint of the human gut microbiota. Nature 568, 499-504, doi:10.1038/s41586-019-0965-1 (2019). 63 Tang, Q. et al. Current Sampling Methods for Gut Microbiota: A Call for More Precise Devices. Frontiers in Cellular and Infection Microbiology 10, doi:10.3389/fcimb.2020.00151 (2020). 64 Gao, R., Gao, Z., Huang, L. & Qin, H. Gut microbiota and colorectal cancer. Eur J Clin Microbiol Infect Dis 36, 757-769, doi:10.1007/s10096-016-2881-8 (2017). 65 Chung, H. et al. Gut immune maturation depends on colonization with a host- specific microbiota. Cell 149, 1578-1593, doi:10.1016/j.cell.2012.04.037 (2012). 66 Tilg, H., Adolph, T. E., Gerner, R. R. & Moschen, A. R. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell 33, 954-964, doi:https://doi.org/10.1016/j.ccell.2018.03.004 (2018). 67 Gagnière, J. et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 22, 501-518, doi:10.3748/wjg.v22.i2.501 (2016). 68 Chen, W., Liu, F., Ling, Z., Tong, X. & Xiang, C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 7, e39743, doi:10.1371/journal.pone.0039743 (2012). 69 Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120-123, doi:10.1126/science.1224820 (2012). 70 Bonnet, M. et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 20, 859-867, doi:10.1158/1078-0432.Ccr-13-1343 (2014). 71 Kohoutova, D. et al. Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect Dis 14, 733, doi:10.1186/s12879-014-0733-7 (2014). 72 Feng, Q. et al. Gut microbiome development along the colorectal adenoma- carcinoma sequence. Nat Commun 6, 6528, doi:10.1038/ncomms7528 (2015). 73 Nakatsu, G. et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun 6, 8727, doi:10.1038/ncomms9727 (2015). 74 Ito, M. et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 137, 1258-1268, doi:10.1002/ijc.29488 (2015). 75 Flemer, B. et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 66, 633-643, doi:10.1136/gutjnl-2015-309595 (2017). 76 Cheng, Y., Ling, Z. & Li, L. The Intestinal Microbiota and Colorectal Cancer. Frontiers in Immunology 11, doi:10.3389/fimmu.2020.615056 (2020). 77 Castellarin, M. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22, 299-306, doi:10.1101/gr.126516.111 (2012). 78 Ohkusa, T. et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 52, 79- 83, doi:10.1136/gut.52.1.79 (2003). 79 Momen-Heravi, F. et al. Periodontal disease, tooth loss and colorectal cancer risk: Results from the Nurses' Health Study. Int J Cancer 140, 646-652, doi:10.1002/ijc.30486 (2017). 80 Flanagan, L. et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 33, 1381-1390, doi:10.1007/s10096-014-2081-3 (2014). 81 Mima, K. et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65, 1973-1980, doi:10.1136/gutjnl-2015-310101 (2016). 82 Nosho, K. et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 22, 557-566, doi:10.3748/wjg.v22.i2.557 (2016). 83 Mima, K. et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol 1, 653-661, doi:10.1001/jamaoncol.2015.1377 (2015). 84 Yu, T. et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell 170, 548-563.e516, doi:10.1016/j.cell.2017.07.008 (2017). 85 Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443-1448, doi:10.1126/science.aal5240 (2017). 86 Gur, C. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344-355, doi:10.1016/j.immuni.2015.01.010 (2015). 87 Yang, Y. et al. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA- 21. Gastroenterology 152, 851-866.e824, doi:10.1053/j.gastro.2016.11.018 (2017). 88 Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195-206, doi:10.1016/j.chom.2013.07.012 (2013). 89 Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207- 215, doi:10.1016/j.chom.2013.07.007 (2013). 90 Denizot, J. et al. Diet-induced hypoxia responsive element demethylation increases CEACAM6 expression, favouring Crohn's disease-associated Escherichia coli colonisation. Gut 64, 428-437, doi:10.1136/gutjnl-2014-306944 (2015). 91 Agus, A. et al. Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation. Sci Rep 6, 19032, doi:10.1038/srep19032 (2016). 92 Veziant, J. et al. Association of colorectal cancer with pathogenic Escherichia coli: Focus on mechanisms using optical imaging. World J Clin Oncol 7, 293-301, doi:10.5306/wjco.v7.i3.293 (2016). 93 Arthur, J. C. et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun 5, 4724, doi:10.1038/ncomms5724 (2014). 94 Cuevas-Ramos, G. et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A 107, 11537-11542, doi:10.1073/pnas.1001261107 (2010). 95 Cougnoux, A. et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 63, 1932-1942, doi:10.1136/gutjnl-2013-305257 (2014). 96 Cougnoux, A. et al. Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. Gut 65, 278-285, doi:10.1136/gutjnl-2014-307241 (2016). 97 Sears, C. L., Geis, A. L. & Housseau, F. Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest 124, 4166-4172, doi:10.1172/jci72334 (2014). 98 Boleij, A. et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 60, 208-215, doi:10.1093/cid/ciu787 (2015). 99 DeStefano Shields, C. E. et al. Reduction of Murine Colon Tumorigenesis Driven by Enterotoxigenic Bacteroides fragilis Using Cefoxitin Treatment. J Infect Dis 214, 122-129, doi:10.1093/infdis/jiw069 (2016). 100 Goodwin, A. C. et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci U S A 108, 15354-15359, doi:10.1073/pnas.1010203108 (2011). 101 Boleij, A., van Gelder, M. M., Swinkels, D. W. & Tjalsma, H. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis 53, 870-878, doi:10.1093/cid/cir609 (2011). 102 Balamurugan, R., Rajendiran, E., George, S., Samuel, G. V. & Ramakrishna, B. S. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol 23, 1298-1303, doi:10.1111/j.1440- 1746.2008.05490.x (2008). 103 Long, X. et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol 4, 2319-2330, doi:10.1038/s41564-019-0541-3 (2019). 104 Kovatcheva-Datchary, P., Tremaroli, V. & Bäckhed, F. in The Prokaryotes: Human Microbiology (eds Eugene Rosenberg et al.) 3-24 (Springer Berlin Heidelberg, 2013). 105 van den Bogert, B., de Vos, W. M., Zoetendal, E. G. & Kleerebezem, M. Microarray analysis and barcoded pyrosequencing provide consistent microbial profiles depending on the source of human intestinal samples. Appl Environ Microbiol 77, 2071-2080, doi:10.1128/aem.02477-10 (2011). 106 Lepage, P. et al. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm Bowel Dis 11, 473-480, doi:10.1097/01.mib.0000159662.62651.06 (2005). 107 Zoetendal, E. G. et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. The ISME Journal 6, 1415-1426, doi:10.1038/ismej.2011.212 (2012). 108 Thomas, V., Clark, J. & Doré, J. Fecal microbiota analysis: an overview of sample collection methods and sequencing strategies. Future Microbiol 10, 1485-1504, doi:10.2217/fmb.15.87 (2015). 109 Wu, G. D. et al. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiology 10, 206, doi:10.1186/1471-2180-10-206 (2010). 110 Fouhy, F. et al. The Effects of Freezing on Faecal Microbiota as Determined Using MiSeq Sequencing and Culture-Based Investigations. PLOS ONE 10, e0119355, doi:10.1371/journal.pone.0119355 (2015). 111 Cardona, S. et al. Storage conditions of intestinal microbiota matter in metagenomic analysis. BMC Microbiology 12, 158, doi:10.1186/1471-2180-12- 158 (2012). 112 Chen, J. & Huang, X. F. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther 8, 1313-1317, doi:10.4161/cbt.8.14.8983 (2009). 113 Meng, M. et al. The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother 140, 111717, doi:10.1016/j.biopha.2021.111717 (2021). 114 Wang, X. W. & Zhang, Y. J. Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol 20, 4178-4188, doi:10.3748/wjg.v20.i15.4178 (2014). 115 Banerjee, N., Kim, H., Talcott, S. & Mertens-Talcott, S. Pomegranate polyphenolics suppressed azoxymethane-induced colorectal aberrant crypt foci and inflammation: possible role of miR-126/VCAM-1 and miR- 126/PI3K/AKT/mTOR. Carcinogenesis 34, 2814-2822, doi:10.1093/carcin/bgt295 (2013). 116 Bian, J., Dannappel, M., Wan, C. & Firestein, R. Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer. Cells 9, 2125 (2020). 117 Bhattacharya, I., Barman, N., Maiti, M. & Sarkar, R. Assessment of beta-catenin expression by immunohistochemistry in colorectal neoplasms and its role as an additional prognostic marker in colorectal adenocarcinoma. Med Pharm Rep 92, 246-252, doi:10.15386/mpr-1218 (2019). 118 Itatani, Y., Kawada, K. & Sakai, Y. Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment. Int J Mol Sci 20, doi:10.3390/ijms20235822 (2019). 119 Makkar, S. et al. Hyaluronic Acid Binding to TLR4 Promotes Proliferation and Blocks Apoptosis in Colon Cancer. Molecular Cancer Therapeutics, doi:10.1158/1535-7163.mct-18-1225 (2019). 120 Li, C., Lau, H. C.-H., Zhang, X. & Yu, J. Mouse Models for Application in Colorectal Cancer: Understanding the Pathogenesis and Relevance to the Human Condition. Biomedicines 10, 1710 (2022). 121 Neufert, C., Becker, C. & Neurath, M. F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2, 1998-2004, doi:10.1038/nprot.2007.279 (2007). 122 Guda, K. et al. Multistage gene expression profiling in a differentially susceptible mouse colon cancer model. Cancer letters 191, 17-25 (2003). 123 Rosenberg, D. W., Giardina, C. & Tanaka, T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 30, 183-196 (2009). 124 Qin, C., Malykhina, A. P., Akbarali, H. I., Meerveld, B. G. V. & Foreman, R. D. Acute Colitis Enhances Responsiveness of Lumbosacral Spinal Neurons to Colorectal Distension in Rats. Digestive Diseases and Sciences, doi:10.1007/s10620-007-9835-z (2007). 125 Okamura, M., Yoh, K., Ojima, M., Morito, N. & Takahashi, S. Overexpression of GATA-3 in T Cells Accelerates Dextran Sulfate Sodium-Induced Colitis. Experimental Animals, doi:10.1538/expanim.63.133 (2014). 126 Yamada. Chemopreventive Effect of Fermented Brown Rice and Rice Bran (FBRA) on the Inflammation-Related Colorectal Carcinogenesis in ApcMin/+ Mice. Oncology Reports, doi:10.3892/or_00000605 (2009). 127 Perše, M. & Cerar, A. Dextran Sodium Sulphate Colitis Mouse Model: Traps and Tricks. Journal of Biomedicine and Biotechnology, doi:10.1155/2012/718617 (2012). 128 Yang, X. et al. Purple Yam Polyphenol Extracts Exert Anticolitis and Anticolitis- Associated Colorectal Cancer Effects Through Inactivation of NF-κB/p65 and STAT3 Signaling Pathways. Journal of Agricultural and Food Chemistry, doi:10.1021/acs.jafc.3c00346 (2023). 129 Aldini, R. et al. Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study. Plos One, doi:10.1371/journal.pone.0108112 (2014). 130 Kodama, T. et al. Fecal microRNA223 as an Indicator of Recovery in Chronic DSS Colitis Model in Rats. Fundamental Toxicological Sciences, doi:10.2131/fts.9.103 (2022). 131 Kawaguchi, M. et al. Ghrelin Administration Suppresses Inflammation‐associated Colorectal Carcinogenesis in Mice. Cancer Science, doi:10.1111/cas.12725 (2015). 132 Akao, T., Oyanagi, Y., Shiotsuki, S., Ikoma, Y. & Sasahara, M. Metabolism of Dextran Sulfate Sodium by Intestinal Bacteria in Rat Cecum Is Related to Induction of Colitis. Biological and Pharmaceutical Bulletin, doi:10.1248/bpb.b14-00708 (2015). 133 Brown, S. et al. Myd88-Dependent Positioning of Ptgs2-Expressing Stromal Cells Maintains Colonic Epithelial Proliferation During Injury. Journal of Clinical Investigation, doi:10.1172/jci29159 (2007). 134 Radeva, G. et al. Regulation of the Oligopeptide Transporter, PEPT-1, in DSS- Induced Rat Colitis. Digestive Diseases and Sciences, doi:10.1007/s10620-006- 9667-2 (2007). 135 Mähler, M. et al. Differential Susceptibility of Inbred Mouse Strains to Dextran Sulfate Sodium-Induced Colitis. Ajp Gastrointestinal and Liver Physiology, doi:10.1152/ajpgi.1998.274.3.g544 (1998). 136 Francia, R. D. et al. Pharmacogenetic-Based Interactions Between Nutraceuticals and Angiogenesis Inhibitors. Cells, doi:10.3390/cells8060522 (2019). 137 Hui, A. et al. Enhancement of Brain-Targeting Delivery of Danshensu in Rat Through Conjugation With Pyrazine Moiety to Form Danshensu-Pyrazine Ester. Drug Delivery and Translational Research, doi:10.1007/s13346-018-0501-0 (2018). 138 Satka, S. et al. Effect of DSS-Induced Ulcerative Colitis and Butyrate on the Cytochrome P450 2A5: Contribution of the Microbiome. International Journal of Molecular Sciences, doi:10.3390/ijms231911627 (2022). 139 Ying, J. et al. Pharmacokinetics Of Active Ingredients of Salvia Miltiorrhiza and Carthamus Tinctorius in Compatibility in Normal and Cerebral Ischemia Rats: A Comparative Study. European Journal of Drug Metabolism and Pharmacokinetics, doi:10.1007/s13318-019-00597-1 (2019). 140 Itzkowitz, S. H. & Yio, X. Inflammation and Cancer IV. Colorectal Cancer in Inflammatory Bowel Disease: The Role of Inflammation. Ajp Gastrointestinal and Liver Physiology, doi:10.1152/ajpgi.00079.2004 (2004). 141 Zuo, B.-W. et al. Boris knockout eliminates AOM/DSS-induced in situ colorectal cancer by suppressing DNA damage repair and inflammation. Cancer Science 114, 1972-1985, doi:https://doi.org/10.1111/cas.15732 (2023). 142 Shao, F. et al. Sulforaphane Attenuates AOM/DSS-induced Colorectal Tumorigenesis in Mice via Inhibition of Intestinal Inflammation. doi:10.21203/rs.3.rs-2057089/v1 (2022). 143 Kim, H.-Y., Song, J. L., Chang, H.-K., Kang, S.-A. & Park, K.-Y. Kimchi Protects Against Azoxymethane/Dextran Sulfate Sodium–Induced Colorectal Carcinogenesis in Mice. Journal of Medicinal Food, doi:10.1089/jmf.2013.2986 (2014). 144 Bauer, C. et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192-1199, doi:10.1136/gut.2009.197822 (2010). 145 Laroui, H. et al. Dextran Sodium Sulfate (DSS) Induces Colitis in Mice by Forming Nano-Lipocomplexes With Medium-Chain-Length Fatty Acids in the Colon. Plos One, doi:10.1371/journal.pone.0032084 (2012). 146 Nagao, K. & Yanagita, T. Medium-Chain Fatty Acids: Functional Lipids for the Prevention and Treatment of the Metabolic Syndrome. Pharmacological Research, doi:10.1016/j.phrs.2009.11.007 (2010). 147 Page, K. A. et al. Medium-Chain Fatty Acids Improve Cognitive Function in Intensively Treated Type 1 Diabetic Patients and Support in Vitro Synaptic Transmission During Acute Hypoglycemia. Diabetes, doi:10.2337/db08-1557 (2009). 148 Scher, J. U. et al. Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease. Arthritis & Rheumatology, doi:10.1002/art.38892 (2014). 149 Basson, A. R. et al. Regulation of Intestinal Inflammation by Dietary Fats. Frontiers in Immunology, doi:10.3389/fimmu.2020.604989 (2021). 150 Liberato, M. V. et al. Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) Γ Activators and Pan-Ppar Partial Agonists. Plos One, doi:10.1371/journal.pone.0036297 (2012). 151 Zhang, Q. et al. Accelerated Dysbiosis of Gut Microbiota During Aggravation of DSS-induced Colitis by a Butyrate-Producing Bacterium. Scientific Reports, doi:10.1038/srep27572 (2016). 152 Zhang, J. et al. Vitexin Protects Against Dextran Sodium Sulfate-Induced Colitis in Mice and Its Potential Mechanisms. Journal of Agricultural and Food Chemistry, doi:10.1021/acs.jafc.2c05177 (2022). 153 Zhang, F. et al. HIPK2 Phosphorylates HDAC3 for NF-κB Acetylation to Ameliorate Colitis-Associated Colorectal Carcinoma and Sepsis. Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2021798118 (2021). 154 Bi, Y. et al. Aryl hydrocarbon receptor nuclear translocator limits the recruitment and function of regulatory neutrophils against colorectal cancer by regulating the gut microbiota. J Exp Clin Cancer Res 42, 53, doi:10.1186/s13046-023-02627-y (2023). 155 Quaglio, A. E. V., Grillo, T. G., De Oliveira, E. C. S., Di Stasi, L. C. & Sassaki, L. Y. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol 28, 4053-4060, doi:10.3748/wjg.v28.i30.4053 (2022). 156 Ye, J. et al. Role of gut microbiota in the pathogenesis and treatment of diabetes mullites: Advanced research-based review. Front Microbiol 13, 1029890, doi:10.3389/fmicb.2022.1029890 (2022). 157 Pizzorno, J. E. & Murray, M. T. Textbook of natural medicine. 4th ed edn, (Elsevier/Churchill Livingstone St. Louis, Mo., 2013). 158 Dunne, C. et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 73, 386s-392s, doi:10.1093/ajcn/73.2.386s (2001). 159 Fuller, R. Probiotics in human medicine. Gut 32, 439-442, doi:10.1136/gut.32.4.439 (1991). 160 Fuller, R. & Gibson, G. R. Modification of the intestinal microflora using probiotics and prebiotics. Scand J Gastroenterol Suppl 222, 28-31, doi:10.1080/00365521.1997.11720714 (1997). 161 Mack, D. R., Michail, S., Wei, S., McDougall, L. & Hollingsworth, M. A. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 276, G941-950, doi:10.1152/ajpgi.1999.276.4.G941 (1999). 162 Wilson, K. H. & Perini, F. Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 56, 2610-2614, doi:10.1128/iai.56.10.2610-2614.1988 (1988). 163 Rolfe, R. D. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 130, 396s-402s, doi:10.1093/jn/130.2.396S (2000). 164 Juven, B. J., Meinersmann, R. J. & Stern, N. J. Antagonistic effects of lactobacilli and pediococci to control intestinal colonization by human enteropathogens in live poultry. J Appl Bacteriol 70, 95-103, doi:10.1111/j.1365-2672.1991.tb04433.x (1991). 165 Mishra, C. & Lambert, J. Production of anti-microbial substances by probiotics. Asia Pac J Clin Nutr 5, 20-24 (1996). 166 Link-Amster, H., Rochat, F., Saudan, K. Y., Mignot, O. & Aeschlimann, J. M. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 10, 55- 63, doi:10.1111/j.1574-695X.1994.tb00011.x (1994). 167 Schiffrin, E. J., Rochat, F., Link-Amster, H., Aeschlimann, J. M. & Donnet- Hughes, A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 78, 491-497, doi:10.3168/jds.S0022- 0302(95)76659-0 (1995). 168 Khalighi, A., Behdani, R. & Kouhestani, S. (2016). 169 Wilkins, T. & Sequoia, J. Probiotics for gastrointestinal conditions: a summary of the evidence. American family physician 96, 170-178 (2017). 170 Goldstein, E. J., Tyrrell, K. L. & Citron, D. M. Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clinical Infectious Diseases 60, S98- S107 (2015). 171 Danilenko, V. et al. Common inflammatory mechanisms in COVID-19 and Parkinson’s diseases: The role of microbiome, pharmabiotics and postbiotics in their prevention. Journal of Inflammation Research 14, 6349 (2021). 172 María Remes-Troche, J. et al. Lactobacillus acidophilus LB: A useful pharmabiotic for the treatment of digestive disorders. Therapeutic advances in gastroenterology 13, 1756284820971201 (2020). 173 Cohen, S. et al. Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over‐the‐counter probiotic formulations. Transplant Infectious Disease 18, 699- 705 (2016). 174 Dani, C. et al. Lactobacillus sepsis and probiotic therapy in newborns: two new cases and literature review. American Journal of Perinatology Reports, e25-e29 (2015). 175 Snydman, D. R. The safety of probiotics. Clinical infectious diseases 46, S104- S111 (2008). 176 Doron, S. & Snydman, D. R. Risk and safety of probiotics. Clinical Infectious Diseases 60, S129-S134 (2015). 177 Goldin, B. R., Gualtieri, L. J. & Moore, R. P. The effect of Lactobacillus GG on the initiation and promotion of DMH-induced intestinal tumors in the rat. Nutr Cancer 25, 197-204, doi:10.1080/01635589609514442 (1996). 178 McIntosh, G. H., Royle, P. J. & Playne, M. J. A probiotic strain of L. acidophilus reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats. Nutr Cancer 35, 153-159, doi:10.1207/s15327914nc352_9 (1999). 179 Mao, Y. et al. The effects of Lactobacillus strains and oat fiber on methotrexate- induced enterocolitis in rats. Gastroenterology 111, 334-344, doi:10.1053/gast.1996.v111.pm8690198 (1996). 180 Doncheva, N. I., Antov, G. P., Softova, E. B. & Nyagolov, Y. P. Experimental and clinical study on the hypolipidemic and antisclerotic effect of Lactobacillus bulgaricus strain GB N 1 (48). Nutrition research 22, 393-403 (2002). 181 Cremonini, F. et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 97, 2744-2749, doi:10.1111/j.1572-0241.2002.07063.x (2002). 182 Hoyos, A. B. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 3, 197-202, doi:10.1016/s1201- 9712(99)90024-3 (1999). 183 Duc le, H., Hong, H. A., Barbosa, T. M., Henriques, A. O. & Cutting, S. M. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol 70, 2161-2171, doi:10.1128/aem.70.4.2161-2171.2004 (2004). 184 Velraeds, M. M., van der Mei, H. C., Reid, G. & Busscher, H. J. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl Environ Microbiol 62, 1958-1963, doi:10.1128/aem.62.6.1958-1963.1996 (1996). 185 Hyronimus, B., Le Marrec, C. & Urdaci, M. C. Coagulin, a bacteriocin-like inhibitory substance produced by Bacillus coagulans I4. J Appl Microbiol 85, 42- 50, doi:10.1046/j.1365-2672.1998.00466.x (1998). 186 Buts, J.-P. Lyophilized Saccharomyces boulardii: example of a probiotic medicine. Revista de gastroenterologia del Peru: organo oficial de la Sociedad de Gastroenterologia del Peru 25, 176-188 (2005). 187 Fietto, J. L. et al. Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Canadian journal of microbiology 50, 615-621 (2004). 188 Posteraro, B. et al. Molecular tools for differentiating probiotic and clinical strains of Saccharomyces cerevisiae. International journal of food microbiology 103, 295- 304 (2005). 189 Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L. & Trinchieri, G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 45, 17-31, doi:10.1002/eji.201444972 (2015). 190 Wong, S. H. et al. Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and Conventional Mice. Gastroenterology 153, 1621-1633.e1626, doi:10.1053/j.gastro.2017.08.022 (2017). 191 De Almeida, C. V., de Camargo, M. R., Russo, E. & Amedei, A. Role of diet and gut microbiota on colorectal cancer immunomodulation. World J Gastroenterol 25, 151-162, doi:10.3748/wjg.v25.i2.151 (2019). 192 Vivarelli, S. et al. Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers (Basel) 11, doi:10.3390/cancers11010038 (2019). 193 Shanshal, S. et al. Impact of peptic ulcer disease on the quality of life: A Cross Sectional Study. Research Journal of Pharmacy and Technology, doi:10.52711/0974-360X.2022.00548 (2022). 194 Sivamaruthi, B. S., Kesika, P. & Chaiyasut, C. The Role of Probiotics in Colorectal Cancer Management. Evid Based Complement Alternat Med 2020, 3535982, doi:10.1155/2020/3535982 (2020). 195 Lu, K., Dong, S., Wu, X., Jin, R. & Chen, H. Probiotics in Cancer. Front Oncol 11, 638148, doi:10.3389/fonc.2021.638148 (2021). 196 Lucas, C., Barnich, N. & Nguyen, H. T. T. Microbiota, Inflammation and Colorectal Cancer. Int J Mol Sci 18, doi:10.3390/ijms18061310 (2017). 197 Fijan, S. Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health 11, 4745-4767, doi:10.3390/ijerph110504745 (2014). 198 Kahouli, I., Tomaro-Duchesneau, C. & Prakash, S. Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. J Med Microbiol 62, 1107-1123, doi:10.1099/jmm.0.048975-0 (2013). 199 Rao, R. K. & Samak, G. Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications. Curr Nutr Food Sci 9, 99-107, doi:10.2174/1573401311309020004 (2013). 200 Hsieh, C. Y. et al. Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum. Physiol Rep 3, doi:10.14814/phy2.12327 (2015). 201 Blackwood, B. P. et al. Probiotic Lactobacillus Species Strengthen Intestinal Barrier Function and Tight Junction Integrity in Experimental Necrotizing Enterocolitis. J Probiotics Health 5, doi:10.4172/2329-8901.1000159 (2017). 202 Dos Reis, S. A. et al. Review of the mechanisms of probiotic actions in the prevention of colorectal cancer. Nutr Res 37, 1-19, doi:10.1016/j.nutres.2016.11.009 (2017). 203 Morrison, D. J. & Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7, 189-200, doi:10.1080/19490976.2015.1134082 (2016). 204 Bassaganya-Riera, J. et al. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis. PLoS One 7, e31238, doi:10.1371/journal.pone.0031238 (2012). 205 Uccello, M. et al. Potential role of probiotics on colorectal cancer prevention. BMC Surg 12 Suppl 1, S35, doi:10.1186/1471-2482-12-s1-s35 (2012). 206 Wang, Y. et al. Antioxidant Properties of Probiotic Bacteria. Nutrients 9, doi:10.3390/nu9050521 (2017). 207 Lan, A., Lagadic-Gossmann, D., Lemaire, C., Brenner, C. & Jan, G. Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propionibacteria. Apoptosis 12, 573-591, doi:10.1007/s10495-006-0010-3 (2007). 208 Ashraf, R., Vasiljevic, T., Day, S. L., Smith, S. & Donkor, O. Lactic acid bacteria and probiotic organisms induce different cytokine profile and regulatory T cells mechanisms. Journal of Functional Foods 6, doi:10.1016/j.jff.2013.11.006 (2013). 209 de Vos, W. M. & de Vos, E. A. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 70 Suppl 1, S45-56, doi:10.1111/j.1753-4887.2012.00505.x (2012). 210 Parker, E. A., Roy, T., D'Adamo, C. R. & Wieland, L. S. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition 45, 125-134.e111, doi:10.1016/j.nut.2017.06.024 (2018). 211 Sanders, M. E. Probiotics: definition, sources, selection, and uses. Clin Infect Dis 46 Suppl 2, S58-61; discussion S144-151, doi:10.1086/523341 (2008). 212 Henker, J. et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 166, 311-318, doi:10.1007/s00431- 007-0419-x (2007). 213 Malchow, H. A. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25, 653- 658, doi:10.1097/00004836-199712000-00021 (1997). 214 Kligler, B. & Cohrssen, A. Probiotics. Am Fam Physician 78, 1073-1078 (2008). 215 Hu, Y. et al. The Bidirectional Interactions between Resveratrol and Gut Microbiota: An Insight into Oxidative Stress and Inflammatory Bowel Disease Therapy. Biomed Res Int 2019, 5403761, doi:10.1155/2019/5403761 (2019). 216 Mercier-Bonin, M. & Chapot-Chartier, M. P. Surface Proteins of Lactococcus lactis: Bacterial Resources for Muco-adhesion in the Gastrointestinal Tract. Front Microbiol 8, 2247, doi:10.3389/fmicb.2017.02247 (2017). 217 Yam, K. K. et al. Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. J Med Microbiol 60, 1248-1260, doi:10.1099/jmm.0.029959-0 (2011). 218 Carvalho, R. D. O. et al. Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis. Front Microbiol 8, 800, doi:10.3389/fmicb.2017.00800 (2017). 219 Vandenbroucke, K. et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 3, 49-56, doi:10.1038/mi.2009.116 (2010). 220 Gomes-Santos, A. C. et al. Hsp65-Producing Lactococcus lactis Prevents Inflammatory Intestinal Disease in Mice by IL-10- and TLR2-Dependent Pathways. Front Immunol 8, 30, doi:10.3389/fimmu.2017.00030 (2017). 221 Li, S. C., Lin, H. P., Chang, J. S. & Shih, C. K. Lactobacillus Acidophilus- Fermented Germinated Brown Rice Suppresses Preneoplastic Lesions of the Colon in Rats. Nutrients, doi:10.3390/nu11112718 (2019). 222 Cevallos, S. A. et al. Increased Epithelial Oxygenation Links Colitis to an Expansion of Tumorigenic Bacteria. Mbio, doi:10.1128/mbio.02244-19 (2019). 223 Wibowo, A. A. et al. An Increase in Inflammatory Cells Related to the Increase Incidence of Colitis and Colorectal Cancer. Bali Medical Journal, doi:10.15562/bmj.v11i1.2842 (2022). 224 Iamartino, L., Elajnaf, T., Kállay, E. & Schepelmann, M. Calcium-Sensing Receptor in Colorectal Inflammation and Cancer: Current Insights and Future Perspectives. World Journal of Gastroenterology, doi:10.3748/wjg.v24.i36.4119 (2018). 225 Aoki, T. & Narumiya, S. Prostaglandin E2-Ep2 Signaling as a Node of Chronic Inflammation in the Colon Tumor Microenvironment. Inflammation and Regeneration, doi:10.1186/s41232-017-0036-7 (2017). 226 Liang, X., Li, H., Tian, G. & Li, S. Dynamic Microbe and Molecule Networks in a Mouse Model of Colitis-Associated Colorectal Cancer. Scientific Reports, doi:10.1038/srep04985 (2014). 227 Kesselring, R., Jauch, D. & Fichtner‐Feigl, S. Interleukin 21 Impairs Tumor Immunosurveillance of Colitis-Associated Colorectal Cancer. Oncoimmunology, doi:10.4161/onci.19407 (2012). 228 Ida, S. et al. SPINK1 Status in Colorectal Cancer, Impact on Proliferation, and Role in Colitis-Associated Cancer. Molecular Cancer Research, doi:10.1158/1541-7786.mcr-14-0581 (2015). 229 Yamaji, N. et al. Hepatocyte Growth Factor Ameliorates Mucosal Injuries Leading to Inhibition of Colon Cancer Development in Mice. Oncology Reports, doi:10.3892/or.2011.1294 (2011). 230 Hyun, C. K. Molecular and Pathophysiological Links Between Metabolic Disorders and Inflammatory Bowel Diseases. International Journal of Molecular Sciences, doi:10.3390/ijms22179139 (2021). 231 Luu, M. & Visekruna, A. Short‐chain Fatty Acids: Bacterial Messengers Modulating the Immunometabolism of T Cells. European Journal of Immunology, doi:10.1002/eji.201848009 (2019). 232 Zhang, X. et al. Widespread Protein Lysine Acetylation in Gut Microbiome and Its Alterations in Patients With Crohn’s Disease. Nature Communications, doi:10.1038/s41467-020-17916-9 (2020). 233 Sun, M., Wu, W., Liu, Z. & Cong, Y. Microbiota Metabolite Short Chain Fatty Acids, GPCR, and Inflammatory Bowel Diseases. Journal of Gastroenterology, doi:10.1007/s00535-016-1242-9 (2016). 234 Miyamoto, J. et al. Nutritional Signaling via Free Fatty Acid Receptors. International Journal of Molecular Sciences, doi:10.3390/ijms17040450 (2016). 235 Braat, H. et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4, 754-759, doi:10.1016/j.cgh.2006.03.028 (2006). 236 Kaczmarek, K., Więckiewicz, J., Węglarczyk, K., Siedlar, M. & Baran, J. The Anti-Tumor Effect of Lactococcus lactis Bacteria-Secreting Human Soluble TRAIL Can Be Enhanced by Metformin Both In Vitro and In Vivo in a Mouse Model of Human Colorectal Cancer. Cancers (Basel) 13, doi:10.3390/cancers13123004 (2021). 237 Zahirović, A., Plavec, T. V. & Berlec, A. Dual Functionalized Lactococcus lactis Shows Tumor Antigen Targeting and Cytokine Binding in Vitro. Front Bioeng Biotechnol 10, 822823, doi:10.3389/fbioe.2022.822823 (2022). 238 Calle, M. L. Statistical Analysis of Metagenomics Data. Genomics Inform 17, e6, doi:10.5808/GI.2019.17.1.e6 (2019). 239 Rausch, P. et al. Comparative Analysis of Amplicon and Metagenomic Sequencing Methods Reveals Key Features in the Evolution of Animal Metaorganisms. Microbiome, doi:10.1186/s40168-019-0743-1 (2019). 240 Zhang, X. et al. MetaPro-IQ: A Universal Metaproteomic Approach to Studying Human and Mouse Gut Microbiota. Microbiome, doi:10.1186/s40168-016-0176-z (2016). 241 Heidrich, V. et al. Choice of 16S Ribosomal RNA Primers Impacts Male Urinary Microbiota Profiling. Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.862338 (2022). 242 Hoffman, C. et al. Species-Level Resolution of Female Bladder Microbiota From 16S rRNA Amplicon Sequencing. Msystems, doi:10.1128/msystems.00518-21 (2021). 243 Höyhtyä, M. et al. Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor Α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, doi:10.1093/ibd/izac182 (2022). 244 Oliveira, S. S. et al. Core of the Saliva Microbiome: An Analysis of the MG-RAST Data. BMC Oral Health, doi:10.1186/s12903-021-01719-5 (2021). 245 Liu, Y. et al. Exploring Gut Microbiota in Patients With Colorectal Disease Based on 16S rRNA Gene Amplicon and Shallow Metagenomic Sequencing. Frontiers in Molecular Biosciences, doi:10.3389/fmolb.2021.703638 (2021). 246 Lu, J. et al. Neohesperidin Attenuates Obesity by Altering the Composition of the Gut Microbiota in High‐fat Diet‐fed Mice. The Faseb Journal, doi:10.1096/fj.201903102rr (2020). 247 Meng, Z. et al. Impacts of Penconazole and Its Enantiomers Exposure on Gut Microbiota and Metabolic Profiles in Mice. Journal of Agricultural and Food Chemistry, doi:10.1021/acs.jafc.9b02856 (2019). 248 Zhu, Q. et al. OGUs Enable Effective, Phylogeny-Aware Analysis of Even Shallow Metagenome Community Structures. doi:10.1101/2021.04.04.438427 (2021). 249 Peterson, D., Bonham, K. S., Rowland, S., Pattanayak, C. W. & Klepac‐Ceraj, V. Comparative Analysis of 16S rRNA Gene and Metagenome Sequencing in Pediatric Gut Microbiomes. doi:10.1101/2021.02.20.432118 (2021). 250 He, B. et al. Assessing the Impact of Data Preprocessing on Analyzing Next Generation Sequencing Data. Frontiers in Bioengineering and Biotechnology 8, doi:10.3389/fbioe.2020.00817 (2020). 251 Simbolo, M. et al. DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One 8, e62692, doi:10.1371/journal.pone.0062692 (2013). 252 Yaman, C. et al. Community Structure of Bacteria and Archaea Associated with Geotextile Filters in Anaerobic Bioreactor Landfills. Processes 9 (2021). 253 Rahayu, T. et al. Metagenomic data of bacterial 16S rRNA in the cemetery soil samples in Surakarta City, Indonesia. Data in Brief 52, 109963, doi:https://doi.org/10.1016/j.dib.2023.109963 (2024). 254 Jovel, J. et al. Characterization of the Gut Microbiome Using 16S or Shotgun Metagenomics. Frontiers in Microbiology, doi:10.3389/fmicb.2016.00459 (2016). 255 Poretsky, R., Rodriguez-R, L. M., Luo, C., Tsementzi, D. & Konstantinidis, K. T. Strengths and Limitations of 16S rRNA Gene Amplicon Sequencing in Revealing Temporal Microbial Community Dynamics. Plos One, doi:10.1371/journal.pone.0093827 (2014). 256 Rezasoltani, S. et al. Signature of Gut Microbiome by Conventional and Advanced Analysis Techniques: Advantages and Disadvantages. Middle East Journal of Digestive Diseases, doi:10.15171/mejdd.2020.157 (2019). 257 Dawson, S. et al. Maternal Prenatal Gut Microbiota Composition Predicts Child Behaviour. Ebiomedicine, doi:10.1016/j.ebiom.2021.103400 (2021). 258 Hu, X. et al. Intermittent Fasting Modulates the Intestinal Microbiota and Improves Obesity and Host Energy Metabolism. NPJ Biofilms and Microbiomes, doi:10.1038/s41522-023-00386-4 (2023). 259 Satoh, S. et al. Phylogeny Analysis of Whole Protein-Coding Genes in Metagenomic Data Detected an Environmental Gradient for the Microbiota. Plos One, doi:10.1371/journal.pone.0281288 (2023). 260 Al-Musharaf, S. et al. Vitamin B12 Status and Gut Microbiota Among Saudi Females With Obesity. Foods, doi:10.3390/foods11244007 (2022). 261 Xy, Z. et al. The Role of Feeding Characteristics in Shaping Gut Microbiota Composition and Function of Ensifera (Orthoptera). Insects, doi:10.3390/insects13080719 (2022). 262 Sharpton, T. J. An Introduction to the Analysis of Shotgun Metagenomic Data. Frontiers in Plant Science, doi:10.3389/fpls.2014.00209 (2014). 263 Nguyen, N.-P., Warnow, T., Pop, M. & White, B. A perspective on 16S rRNA operational taxonomic unit clustering using sequence similarity. npj Biofilms and Microbiomes 2, 16004, doi:10.1038/npjbiofilms.2016.4 (2016). 264 Gupta, S. et al. Amplicon sequencing provides more accurate microbiome information in healthy children compared to culturing. Commun Biol 2, 291, doi:10.1038/s42003-019-0540-1 (2019). 265 Chiarello, M., McCauley, M., Villéger, S. & Jackson, C. R. Ranking the biases: The choice of OTUs vs. ASVs in 16S rRNA amplicon data analysis has stronger effects on diversity measures than rarefaction and OTU identity threshold. PLOS ONE 17, e0264443, doi:10.1371/journal.pone.0264443 (2022). 266 Zhu, R. et al. Comparison of Soil Microbial Community Between Reseeding Grassland and Natural Grassland in Songnen Meadow. Scientific Reports, doi:10.1038/s41598-020-74023-x (2020). 267 Shah, N., Meisel, J. S. & Pop, M. Embracing Ambiguity in the Taxonomic Classification of Microbiome Sequencing Data. Frontiers in Genetics, doi:10.3389/fgene.2019.01022 (2019). 268 Lie, A. A. Y. et al. Investigating Microbial Eukaryotic Diversity From a Global Census: Insights From a Comparison of Pyrotag and Full-Length Sequences of 18S rRNA Genes. Applied and Environmental Microbiology, doi:10.1128/aem.00057- 14 (2014). 269 Li, L. & Sam, Z. Comparative Power Law Analysis for the Spatial Heterogeneity Scaling of the Hot‐spring Microbiomes. Molecular Ecology, doi:10.1111/mec.15124 (2019). 270 Goldberg, B., Sichtig, H., Geyer, C. N., Ledeboer, N. A. & Weinstock, G. M. Making the Leap From Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation Sequencing in Infectious Disease Diagnostics. Mbio, doi:10.1128/mbio.01888-15 (2015). 271 Krishna, S. et al. Integrating Microbiome Network: Establishing Linkages Between Plants, Microbes and Human Health. The Open Microbiology Journal, doi:10.2174/1874285801913020330 (2019). 272 Maki, K. A. et al. Considerations When Designing a Microbiome Study: Implications for Nursing Science. Biological Research for Nursing, doi:10.1177/1099800418811639 (2018). 273 Nemergut, D. R. et al. Patterns and Processes of Microbial Community Assembly. Microbiology and Molecular Biology Reviews, doi:10.1128/mmbr.00051-12 (2013). 274 Hoorde, K. V. & Butler, F. Use of Next‐generation Sequencing in Microbial Risk Assessment. Efsa Journal, doi:10.2903/j.efsa.2018.e16086 (2018). 275 Cabezas‐Cruz, A. et al. Handling the Microbial Complexity Associated to Ticks. doi:10.5772/intechopen.80511 (2019). 276 Sung, J. et al. Global Metabolic Interaction Network of the Human Gut Microbiota for Context-Specific Community-Scale Analysis. Nature Communications, doi:10.1038/ncomms15393 (2017). 277 Carpi, G. et al. Metagenomic Profile of the Bacterial Communities Associated With Ixodes Ricinus Ticks. Plos One, doi:10.1371/journal.pone.0025604 (2011). 278 Kuperman, R. G. et al. Inhibition of Soil Microbial Activity by Nitrogen‐based Energetic Materials. Environmental Toxicology and Chemistry, doi:10.1002/etc.3862 (2017). 279 Methé, B. A. et al. A Framework for Human Microbiome Research. Nature, doi:10.1038/nature11209 (2012). 280 Huang, H. et al. Panoramic View of a Superfamily of Phosphatases Through Substrate Profiling. Proceedings of the National Academy of Sciences, doi:10.1073/pnas.1423570112 (2015). 281 Börnigen, D. et al. Functional Profiling of the Gut Microbiome in Disease- Associated Inflammation. Genome Medicine, doi:10.1186/gm469 (2013). 282 Fukatsu, T. Next‐generation Sequencing Sheds Light on Intricate Regulation of Insect Gut Microbiota. Molecular Ecology, doi:10.1111/mec.12090 (2012). 283 Goll, J. et al. A Case Study for Large-Scale Human Microbiome Analysis Using JCVI’s Metagenomics Reports (METAREP). Plos One, doi:10.1371/journal.pone.0029044 (2012). 284 McIlroy, J., Ianiro, G., Mukhopadhya, I., Hansen, R. & Hold, G. L. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther 47, 26-42, doi:10.1111/apt.14384 (2018). 285 Tarnecki, A. M., Burgos, F. A., Ray, C. L. & Arias, C. R. Fish intestinal microbiome: diversity and symbiosis unravelled by metagenomics. J Appl Microbiol 123, 2-17, doi:10.1111/jam.13415 (2017). 286 Salimi, A. et al. Dynamic Population of Gut Microbiota as an Indicator of Inflammatory Bowel Disease. Iran Biomed J 26, 350-356, doi:10.52547/ibj.3772 (2022). 287 Cholewińska, P. et al. The Level of Selected Bacterial Phyla on the Skin Surface of Small Ruminants According to the Breed and Species. Animals (Basel) 11, doi:10.3390/ani11092734 (2021). 288 Arias-Giraldo, L. M. et al. Species-dependent variation of the gut bacterial communities across Trypanosoma cruzi insect vectors. PLoS One 15, e0240916, doi:10.1371/journal.pone.0240916 (2020). 289 Shin, N., Whon, T. W. & Bae, J. W. Proteobacteria: Microbial Signature of Dysbiosis in Gut Microbiota. Trends in Biotechnology, doi:10.1016/j.tibtech.2015.06.011 (2015). 290 Nadeau, B. A. & Conjeevaram, H. S. The Gut Microbiome and Nonalcoholic Fatty Liver Disease. Clinical Liver Disease, doi:10.1002/cld.671 (2017). 291 Yulandi, A., Waturangi, D. E., Wahyudi, A. T. & Suwanto, A. Shotgun Metagenomic Analysis Reveals New Insights on Bacterial Community Profiles in Tempeh. doi:10.1101/2020.03.12.988444 (2020). 292 Kumar, J. et al. Metagenomic Insights Into the Taxonomic and Functional Features of Kinema, a Traditional Fermented Soybean Product of Sikkim Himalaya. Frontiers in Microbiology, doi:10.3389/fmicb.2019.01744 (2019). 293 Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105, 16731-16736, doi:10.1073/pnas.0804812105 (2008). 294 Di Pietro, R., Arroyo, L. G., Leclere, M. & Costa, M. C. Species-Level Gut Microbiota Analysis after Antibiotic-Induced Dysbiosis in Horses. Animals (Basel) 11, doi:10.3390/ani11102859 (2021). 295 He, Q. et al. Methyl-Donor Micronutrient for Gestating Sows: Effects on Gut Microbiota and Metabolome in Offspring Piglets. Front Nutr 8, 675640, doi:10.3389/fnut.2021.675640 (2021). 296 Xu, Y. et al. The microbiome types of colorectal tissue are potentially associated with the prognosis of patients with colorectal cancer. Front Microbiol 14, 1100873, doi:10.3389/fmicb.2023.1100873 (2023). 297 Naseri, K. et al. Alterations in the Composition of the Gut Microbiota in Celiac Disease, Non-Coeliac Gluten Sensitivity and Irritable Bowel Syndrome. (2021). 298 Hegde, S. et al. Microbiota dysbiosis and its pathophysiological significance in bowel obstruction. Sci Rep 8, 13044, doi:10.1038/s41598-018-31033-0 (2018). 299 Tsai, H. J. et al. Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients. J Pers Med 11, doi:10.3390/jpm11030238 (2021). 300 Franco-Esquivias, A. P. et al. Gut microbiota in Mexican patients with common variable immunodeficiency. Gac Med Mex 155, 447-452, doi:10.24875/gmm.M20000330 (2019). 301 Zhang, M. et al. Effects of Continuous Cropping of Codonopsis Tangshen on Rhizospheric Soil Bacterial Community as Determined by Pyrosequencing. Diversity, doi:10.3390/d13070317 (2021). 302 Radita, R., Suwanto, A., Kurosawa, N., Wahyudi, A. T. & Rusmana, I. Metagenome Analysis of Tempeh Production: Where Did the Bacterial Community in Tempeh Come From? Malaysian Journal of Microbiology, doi:10.21161/mjm.101417 (2017). 303 Buffie, C. G. & Pamer, E. G. Microbiota-mediated colonization resistance against intestinal pathogens. Nature Reviews Immunology 13, 790-801, doi:10.1038/nri3535 (2013). 304 Xing, C. et al. Interaction between microbiota and immunity and its implication in colorectal cancer. Front Immunol 13, 963819, doi:10.3389/fimmu.2022.963819 (2022). 305 Pollet, T. V., Tadonléké, R. D. & Humbert, J. F. Spatiotemporal Changes in the Structure and Composition of a Less-Abundant Bacterial Phylum (Planctomycetes) in Two Perialpine Lakes. Applied and Environmental Microbiology, doi:10.1128/aem.02697-10 (2011). 306 Zhou, D. et al. Deciphering Microbial Diversity Associated With Fusarium Wilt- Diseased and Disease-Free Banana Rhizosphere Soil. BMC Microbiology, doi:10.1186/s12866-019-1531-6 (2019). 307 Hagerty, S. L., Hutchison, K. E., Lowry, C. A. & Bryan, A. D. An empirically derived method for measuring human gut microbiome alpha diversity: Demonstrated utility in predicting health-related outcomes among a human clinical sample. PLoS One 15, e0229204, doi:10.1371/journal.pone.0229204 (2020). 308 Forbes, J. et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases - Does a common dysbiosis exist? Microbiome 6, doi:10.1186/s40168-018-0603-4 (2018). 309 Wang, S., Yan, Z., Wang, P., Zheng, X. & Fan, J. Comparative Metagenomics Reveals the Microbial Diversity and Metabolic Potentials in the Sediments and Surrounding Seawaters of Qinhuangdao Mariculture Area. Plos One, doi:10.1371/journal.pone.0234128 (2020). 310 Sogin, M. L. et al. Microbial Diversity in the Deep Sea and the Underexplored “Rare Biosphere”. Proceedings of the National Academy of Sciences, doi:10.1073/pnas.0605127103 (2006). 311 Louca, S. et al. Function and Functional Redundancy in Microbial Systems. Nature Ecology & Evolution, doi:10.1038/s41559-018-0519-1 (2018). 312 Delgado‐Baquerizo, M. et al. A Global Atlas of the Dominant Bacteria Found in Soil. Science, doi:10.1126/science.aap9516 (2018). 313 Coyte, K. Z., Schluter, J. & Foster, K. R. The Ecology of the Microbiome: Networks, Competition, and Stability. Science, doi:10.1126/science.aad2602 (2015). 314 Su, X. Elucidating the Beta-Diversity of the Microbiome: from Global Alignment to Local Alignment. mSystems 6, 10.1128/msystems.00363-00321, doi:10.1128/msystems.00363-21 (2021). 315 Chang, Q., Luan, Y. & Sun, F. Variance adjusted weighted UniFrac: a powerful beta diversity measure for comparing communities based on phylogeny. BMC Bioinformatics 12, 118, doi:10.1186/1471-2105-12-118 (2011). 316 Heino, J., Soininen, J., Alahuhta, J., Lappalainen, J. & Virtanen, R. A Comparative Analysis of Metacommunity Types in the Freshwater Realm. Ecology and Evolution, doi:10.1002/ece3.1460 (2015). 317 Lee, S. H. et al. Association Between Cigarette Smoking Status and Composition of Gut Microbiota: Population-Based Cross-Sectional Study. Journal of Clinical Medicine, doi:10.3390/jcm7090282 (2018). 318 López-Delgado, E. O., Winemiller, K. O. & Villa‐Navarro, F. A. Local Environmental Factors Influence Beta‐diversity Patterns of Tropical Fish Assemblages More Than Spatial Factors. Ecology, doi:10.1002/ecy.2940 (2019). 319 Sharma, S., Kelly, T. K. & Jones, P. A. Epigenetics in Cancer. Carcinogenesis, doi:10.1093/carcin/bgp220 (2009). 320 Illikoud, N., Mantel, M., Rolli-Derkinderen, M., Gagnaire, V. & Jan, G. Dairy starters and fermented dairy products modulate gut mucosal immunity. Immunol Lett 251-252, 91-102, doi:10.1016/j.imlet.2022.11.002 (2022). 321 Anjana & Tiwari, S. K. Bacteriocin-Producing Probiotic Lactic Acid Bacteria in Controlling Dysbiosis of the Gut Microbiota. Front Cell Infect Microbiol 12, 851140, doi:10.3389/fcimb.2022.851140 (2022). 322 Ermolenko, E. et al. Influence of different probiotic lactic Acid bacteria on microbiota and metabolism of rats with dysbiosis. Biosci Microbiota Food Health 32, 41-49, doi:10.12938/bmfh.32.41 (2013). 323 Saghari, M. et al. Impact of oral administration of single strain Lactococcus lactis spp. cremoris on immune responses to keyhole limpet hemocyanin immunization and gut microbiota: A randomized placebo-controlled trial in healthy volunteers. Front Immunol 13, 1009304, doi:10.3389/fimmu.2022.1009304 (2022). 324 Yang, B. et al. Lactobacillus ruminis Alleviates DSS-Induced Colitis by Inflammatory Cytokines and Gut Microbiota Modulation. Foods 10, doi:10.3390/foods10061349 (2021). 325 Yeo, S. et al. Anti-Inflammatory and Gut Microbiota Modulatory Effect of Lactobacillus rhamnosus Strain LDTM 7511 in a Dextran Sulfate Sodium-Induced Colitis Murine Model. Microorganisms 8, doi:10.3390/microorganisms8060845 (2020). | |
| local.eprints.dir | disk0/00/47/09/32 | |
| local.eprints.division | S2 | |
| local.eprints.id | 470932 | |
| local.eprints.type | thesis/masters | |
| local.eprints.uri | http://scholar.unand.ac.id/470932/ | |
| local.fakultas | Pascasarjana (S2) | |
| local.identifier.nim | 1850303209 | |
| local.thesis.level | Tesis |
